Skip to main content

AL-S Pharma Announces Positive Topline Results from Phase 2 Study of AP-101 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Written by Kirsten Ruehl on . Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]